Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 11;218(3):e20201097. doi: 10.1084/jem.20201097

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Ablain et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — SPRED1 loss confers resistance to BRAF inhibition in BRAF-driven zebrafish melanoma in vivo and is associated with acquired resistance to targeted therapy in a patient with melanoma. (A) Representative pictures of zebrafish bearing BRAF/tp53 or BRAF/tp53/spred1 tumors and treated daily with 5 µM dabrafenib for 14 d. Scale bar, 1 cm. (B) Quantification of tumor size after 14 d of dabrafenib treatment relative to tumor size before treatment in zebrafish with BRAF/tp53 (n = 13) or BRAF/tp53/spred1 (n = 9) tumors. Pooled data of three independent experiments. **, P = 0.01, two-tailed t test. (C) Circos representation of chromosome 15 copy-number changes of four tumors from a patient who was treated with and responded to dabrafenib plus trametinib. The outermost layer represents the chromosomal regions of chromosome 15, and the inner heatmaps indicate copy-number changes (log2 ratio) averaged in 1-kb genomic windows (from inner to outer: baseline, DD-DP1, DD-DP2, and DD-DP3). Arrow indicates the location of SPRED1.